PT-141 (Bremelanotide)
A melanocortin receptor agonist studied for its effects on sexual function through central nervous system pathways rather than vascular mechanisms.
Mechanism of Action
PT-141 activates melanocortin-4 receptors (MC4R) in the hypothalamus, triggering neural pathways involved in sexual arousal. Unlike PDE5 inhibitors, it acts centrally rather than peripherally, modulating dopaminergic signaling in the medial preoptic area. This mechanism allows it to affect sexual desire and arousal independent of vascular function.
Key Published Studies
Bremelanotide for Female Sexual Dysfunctions: Results From Phase 3 Trial (RECONNECT)
Kingsberg SA, Clayton AH, Pfaus JG — Obstetrics and Gynecology (2019)
Bremelanotide significantly improved sexual desire and reduced distress related to low sexual desire in premenopausal women with HSDD.
PT-141 for the Treatment of Erectile Dysfunction
Diamond LE, Earle DC, Rosen RC, et al. — International Journal of Impotence Research (2004)
PT-141 produced statistically significant improvements in erectile response compared to placebo, demonstrating a novel central mechanism of action.
Dosage Range
Subcutaneous research doses: 0.5-2 mg per administration in clinical studies.
Reconstitution
Reconstitute with bacteriostatic water. For a 10 mg vial, add 2 mL BAC water for a 5 mg/mL solution.
Storage
Store lyophilized powder at -20C. Reconstituted solution at 2-8C, use within 21 days.
Half-Life
Approximately 2.7 hours. Peak activity occurs 1-2 hours post-administration.
Related Products
For Research Use Only. The information on this page is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. All products sold by PrestigePeptides are strictly for laboratory research use and are not intended for human or veterinary consumption.
Ready to start your research?